Cadila Healthcare Sued by Alpex Pharma Over Generic Drug

Cadila Healthcare Ltd. (CDH) a generic-drug maker based in Ahmedabad, India, was sued by Alpex Pharma SA for infringing a U.S. patent for the obesity drug Suprenza.

Alpex, based in Mezzovico, Switzerland, contends Cadila, doing business as Zydus Cadila, wrongly applied to the U.S. Food & Drug Administration to sell low-cost copies of the medicine before the patent expires in 2018, according to a lawsuit filed yesterday in federal court in Wilmington, Delaware.

Unless blocked by a judge, premature sales of the generic drug in the U.S. will cause “substantial and irreparable harm” to Alpex, the company said in court papers.

Sujatha Rajesh, a Cadila spokeswoman, didn’t immediately respond to an e-mailed request for comment on the lawsuit.

The case is Alpex v. Zydus, 13-cv-01143, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 6,149,938.

To contact the reporter on this story: Phil Milford in Wilmington at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.